Atomic AI, a biotechnology company fusing machine learning with structural biology to unlock RNA drug discovery, launched today with a $35 million Series A round. The financing was led by Playground Global, with participation from 8VC, Factory HQ, Greylock, NotBoring, AME Cloud Ventures, and renowned angel investors including GitHub ex-CEO… Read More
A multi-disciplinary team of researchers has developed a way to monitor the progression of movement disorders using motion capture technology and AI. By combining human movement data gathered from wearable tech with a powerful new medical AI technology, the team were able to significantly increase the efficiency… Read More
Listen to this article on the DDW podcast: In 2020, AI models predicted the efficacy of repurposed drugs for Covid-19. Clinical trials revealed eight out of nine predictions were correct. Here Imran S Haque, VP Data Science at Recursion describes the journey of the AI platform behind those predictions. The Covid-19… Read More
Cancer Research Horizons and biotech company Turbine have announced a partnership to solve complex diseases. The partnership will utilise Turbine’s Simulated Cells platform to identify target patient populations who could benefit from CDC7 inhibitor therapy with Cancer Research Horizons’ lead compound CRT’2199. CRT’2199 originates from Cancer Research Horizons’ Therapeutic Innovation. Read More
Potential new drug candidates have been identified by a respiratory syncytial virus (RSV) artificial intelligence programme, as health officials warn of a “tripledemic” of SARS-CoV-2, influenza and RSV. The AI programme, part of a collaboration between Poolbeg Pharma and OneThree, uses Poolbeg’s RSV human challenge… Read More
A project creating a new class of therapeutic proteins to modulate cell signalling has been accepted into the BioInnovation Institute (BII) Bio Studio programme. The project is based on recent breakthroughs in artificial intelligence (AI) and protein design, and uses methods pioneered by David Baker’s laboratory at the University of… Read More
PhoreMost and ThinkCyte have entered a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI). The partnership leverages both companies’ technologies in high-throughput drug discovery, PhoreMost’s phenotypic screening platform, SITESEEKER, and ThinkCyte’s AI-driven cell characterisation and sorting platform, Ghost Cytometry. … Read More
Using artificial intelligence, researchers at Chalmers University of Technology, Sweden have succeeded in designing synthetic DNA that controls the cells’ protein production. The technology can contribute to the development and production of vaccines and drugs for severe diseases much faster and at… Read More
Poolbeg Pharma and partner OneThree Biotech have discovered novel drug targets for the treatment of respiratory syncytial virus (RSV) using an artificial intelligence (AI) programme. The OneThree team, using its AI platform, identified novel drug targets using Poolbeg’s RSV human challenge trial data. The next… Read More
A new system utilising artificial intelligence (AI), ‘building-block’ chemistry and a molecule-making machine could speed up innovation and drug discovery, as well as make complex chemistry automated and accessible. Researchers at the University of Illinois Urbana-Champaign and collaborators in Poland and Canada doubled the average yield of a special, hard-to-optimise… Read More
Listen to this article on the DDW Podcast: David Gray, CSO of Inscopix talks to Lu Rahman about the company’s understanding of the neuroscience market and its quest to improve technologies for neuroscientists to enable multimodal research. Inscopix is a neurotechnology company focused on understanding the function of the brain to… Read More
Listen to this article on the DDW podcast: Reece Armstrong speaks to Natalia Mateu, Co-Founder, Jelena Aleksic, Co-Founder and Peter Curran, Chemoinformatics Scientist, about utilising 3D chemistry and AI to get small molecule therapies from the clinic to the bedside. RA: How is Pharmenable aiming to replicate the specificity of biologics… Read More
A new partnership will bring together Microsoft’s computational services, cloud and artificial intelligence (AI) and Novo Nordisk’s drug discovery, development and data science capabilities. Through the agreement, Microsoft will provide AI technology, foundational science models and expertise and work alongside Novo Nordisk’s data scientists and domain experts to accelerate the… Read More
Nicola Richmond, VP of AI, BenevolentAI, will be speaking at the Tech Theatre, ELRIG Drug Discovery 2022, supported by DDW. Nicola Richmond is a mathematician with over 20 years’ experience of developing digital solutions to problems in drug discovery and development. She will be presenting a talk on ‘The lab… Read More
The Covid-19 pandemic has led to improvements in clinical trial processes and a more technology-driven approach, a new report from Medidata has revealed. The report ‘European Industry Research Report: The Future of Clinical Trials’ includes insights from 400 clinical trial executives across the United Kingdom, France, Germany and Switzerland. The… Read More
Brainomix has partnered with Bridge Biotherapeutics to deliver AI imaging biomarker analysis within the Phase II study of novel autotaxin inhibitor BBT-877 in idiopathic pulmonary fibrosis (IPF). Under the partnership, Brainomix will leverage its e-ILD technology (automated artificial intelligence software) which has been trained to process high resolution chest CT… Read More
